Inovio Pharmaceuticals, Inc. Announces Board Changes
January 03, 2019 at 08:00 am EST
Share
Inovio Pharmaceuticals, Inc. announced that Mr. Simon X. Benito, former Merck Vaccines executive, has been appointed Chairman of Inovio's Board of Directors, replacing Dr. Avtar Dhillon who is retiring from the Board after 10 years of service. Dr. Dhillon was initially appointed as Chairman of the Board in 2009 in conjunction with the merger between Inovio Biomedical and VGX Pharmaceuticals with a mandate to provide continuity and strategic guidance during its integration. Effective immediately, Mr. Benito will assume the role of Chairman. In addition to the appointment of Mr. Benito, Inovio welcomes Ms. Lota Zoth to the company's Board of Directors. Lota Zoth has held senior financial roles in a variety of commercial-stage companies, including serving as MedImmune's chief financial officer. Prior to joining MedImmune, Ms. Zoth served in financial executive roles with PSINet Inc., Sodexho Marriott Services, Inc., Marriott International and PepsiCo, Inc. Ms. Zoth was also an auditor at Ernst & Young, LLP and is a Certified Public Accountant.
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.